Abstract: Diabetes mellitus is one of the most common metabolic complications in kidney transplant recipients and substantially impairs patient prognosis. Sodium⁃glucose co⁃transporter 2 inhibitors (SGLT2i) and glucagon⁃like peptide⁃1 receptor agonists (GLP⁃1RA) are novel antidiabetic agents. Owing to their unique glucose⁃lowering mechanisms and potential cardiorenal protective effects, they have gradually become important options for diabetes management. However, kidney transplant recipients have long been excluded from clinical trials, resulting in a lack of relevant evidence for this specific patient population. In recent years, attention to the potential efficacy and safety of these novel agents in the transplant setting has increased, and both SGLT2i and GLP⁃1RA have shown promising applicability in diabetic kidney transplant recipients. This review is based on a comprehensive literature search of recent studies on SGLT2i and GLP⁃1RA in diabetic kidney transplant recipients, and it summarizes current progress regarding mechanisms of action, clinical benefits, safety considerations, and the potential for combined use, thereby providing a reference for individualized clinical treatment in practice.

Key words: font-family:Inter, -apple-system, BlinkMacSystemFont, ", font-size:16px, background-color:#FFFFFF, ">kidney transplantation、diabetes mellitus、sodium?glucose co?transporter 2 inhibitors、glucagon?like peptide?1 receptor agonists